Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumours

Medicine & Life Sciences

• Immunogenic Cell Death 100%
• diphosphoric acid 84%
• Platinum 66%
• Neoplasms 20%
• Thymoma 12%
• Safety 9%
• Prostatic Neoplasms 8%
• Pharmacokinetics 7%
• Biomarkers 6%
• Response Evaluation Criteria in Solid Tumors 6%
• Tumor-Infiltrating Lymphocytes 6%
• Population 6%
• Small Cell Lung Carcinoma 5%
• Castration 5%
• Peripheral Nervous System Diseases 5%
• Tumor Biomarkers 5%
• Standard of Care 5%
• Progression-Free Survival 4%
• Non-Small Cell Lung Carcinoma 4%
• Nausea 4%
• Fatigue 4%
• Risk Assessment 4%
• Theoretical Models 4%
• Lung Neoplasms 4%
• Therapeutics 3%
• Odds Ratio 3%
• Bone and Bones 3%